ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET FORECAST 2018-2026
KEY FINDINGS
The Asia-Pacific chronic idiopathic constipation drug market is predicted to expand at a CAGR of 10.12% over the forecast period of 2018-2026. The region is considered to be the most promising and lucrative market for CIC drugs and is expected to grow at a considerable pace over the projected years.
MARKET INSIGHTS
The Asian CIC drug market can be segmented by the type of drug and by the type of prescription. The drug lubiprostone is dominating the drug segment closely followed by the drug linaclotide. By prescription type, over the counter drugs are more popular as they can be obtained without a doctor’s prescription. The major driver increasing growth in the Asian market is the modern dietary habits such as intake of foods rich in animal fats, especially dairy products, eggs and meat or foods that have refined sugar and low fibre. Although the market looks promising for the coming years, factors like alternate surgical treatments and the lack of awareness about such drugs in the masses are acting as restraints for market growth.
COMPETITIVE INSIGHTS
Ferring International Center S.A, Progenics Pharmaceuticals Inc Chugai Pharmaceutical, Theravance Biopharma Inc, Allergens, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, GlaxoSmithKline, Pfizer, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Roche Holding Ag ,Merck Sharp & Dohme, Bayer Ag, and Sucampo Pharmaceuticals Inc, are some of the leading companies in this market.
The Asia-Pacific chronic idiopathic constipation drug market is predicted to expand at a CAGR of 10.12% over the forecast period of 2018-2026. The region is considered to be the most promising and lucrative market for CIC drugs and is expected to grow at a considerable pace over the projected years.
MARKET INSIGHTS
The Asian CIC drug market can be segmented by the type of drug and by the type of prescription. The drug lubiprostone is dominating the drug segment closely followed by the drug linaclotide. By prescription type, over the counter drugs are more popular as they can be obtained without a doctor’s prescription. The major driver increasing growth in the Asian market is the modern dietary habits such as intake of foods rich in animal fats, especially dairy products, eggs and meat or foods that have refined sugar and low fibre. Although the market looks promising for the coming years, factors like alternate surgical treatments and the lack of awareness about such drugs in the masses are acting as restraints for market growth.
COMPETITIVE INSIGHTS
Ferring International Center S.A, Progenics Pharmaceuticals Inc Chugai Pharmaceutical, Theravance Biopharma Inc, Allergens, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, GlaxoSmithKline, Pfizer, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Roche Holding Ag ,Merck Sharp & Dohme, Bayer Ag, and Sucampo Pharmaceuticals Inc, are some of the leading companies in this market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. INCREASING DEMAND FOR CIC DRUG FROM APAC MARKET
4.7.2. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS
5. ASIA PACIFIC CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
6. ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRY
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. ASIA PACIFIC CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
8.1. CHINA
8.2. JAPAN
8.3. REST OF ASIA PACIFIC
9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. INCREASING DEMAND FOR CIC DRUG FROM APAC MARKET
4.7.2. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS
5. ASIA PACIFIC CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
6. ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRY
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. ASIA PACIFIC CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
8.1. CHINA
8.2. JAPAN
8.3. REST OF ASIA PACIFIC
9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
LIST OF TABLES
TABLE 1 ASIA PACIFIC CIC DRUG MARKET BY COUNTRIES 2018-2026 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 ASIA PACIFIC CIC DRUGS MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 11 ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 13 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 14 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 15 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
TABLE 16 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 17 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
TABLE 1 ASIA PACIFIC CIC DRUG MARKET BY COUNTRIES 2018-2026 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 ASIA PACIFIC CIC DRUGS MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 11 ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 13 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 14 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 15 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
TABLE 16 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 17 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 2 ASIA PACIFIC CIC DRUG MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
FIGURE 3 ASIA PACIFIC CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 APAC CIC MARKET 2018-2026 ($ MILLION)
FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 12 ASIA PACIFIC LUBIPROSTONE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 13 ASIA PACIFIC LINACLOTIDE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 14 ASIA PACIFIC OTHER DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 15 ASIA PACIFIC PRESCRIBED CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 16 ASIA PACIFIC OVER THE COUNTER CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 17 ASIA PACIFIC CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 18 CHINA CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 19 JAPAN CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 20 REST OF APAC CIC DRUG MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ALLERGENS
2. CHUGAI PHARMACEUTICAL
3. FERRING INTERNATIONAL CENTER S.A.
4. SYNERGY PHARMACEUTICALS
5. PFIZER
6. GLAXOSMITHKLINE
7. ROCHE HOLDING AG
8. SANOFI
9. BAYER AG
10. MERCK SHARP & DOHME
11. ELI LILLY AND COMPANY
12. SALIX PHARMACEUTICALS LTD
13. SUCAMPO PHARMACEUTICALS INC
14. IRONWOOD PHARMACEUTICALS INC
15. VALEANT PHARMACEUTICALS INTERNATIONAL
16. DAIICHI SANKYO CO LTD
17. COSMO PHARMACEUTICALS SA
18. PROGENICS PHARMACEUTICALS INC
19. THERAVANCE BIOPHARMA INC
FIGURE 1 ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 2 ASIA PACIFIC CIC DRUG MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
FIGURE 3 ASIA PACIFIC CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 APAC CIC MARKET 2018-2026 ($ MILLION)
FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 12 ASIA PACIFIC LUBIPROSTONE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 13 ASIA PACIFIC LINACLOTIDE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 14 ASIA PACIFIC OTHER DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 15 ASIA PACIFIC PRESCRIBED CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 16 ASIA PACIFIC OVER THE COUNTER CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 17 ASIA PACIFIC CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 18 CHINA CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 19 JAPAN CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 20 REST OF APAC CIC DRUG MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ALLERGENS
2. CHUGAI PHARMACEUTICAL
3. FERRING INTERNATIONAL CENTER S.A.
4. SYNERGY PHARMACEUTICALS
5. PFIZER
6. GLAXOSMITHKLINE
7. ROCHE HOLDING AG
8. SANOFI
9. BAYER AG
10. MERCK SHARP & DOHME
11. ELI LILLY AND COMPANY
12. SALIX PHARMACEUTICALS LTD
13. SUCAMPO PHARMACEUTICALS INC
14. IRONWOOD PHARMACEUTICALS INC
15. VALEANT PHARMACEUTICALS INTERNATIONAL
16. DAIICHI SANKYO CO LTD
17. COSMO PHARMACEUTICALS SA
18. PROGENICS PHARMACEUTICALS INC
19. THERAVANCE BIOPHARMA INC
